CancerDrs

Lung Cancer clinical trials in Iowa

18 actively recruiting lung cancer trials at 20 sites across Iowa.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Saint Anthony Regional Hospital — Carroll, Iowa
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC)…

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Iowa:
  • Research Site — Waterloo, Iowa
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Iowa:
  • University of Iowa-Holden Comprehensive Cancer Center ( Site 0062) — Iowa City, Iowa
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Iowa:
  • Physicians Clinic of Iowa — Cedar Rapids, Iowa
  • Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics — Iowa City, Iowa
Phase 3 Recruiting Industry

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treat…

Sponsor: BioNTech SE
NCT ID: NCT06712355
Sites in Iowa:
  • McFarland Clinic — Ames, Iowa
  • Helen G. Nassif Community Cancer Center — Cedar Rapids, Iowa
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Mercy Hospital — Cedar Rapids, Iowa
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Iowa:
  • Local Institution - 0065 — Iowa City, Iowa
Phase 2 Recruiting Academic/Other

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be rand…

Sponsor: Greg Durm, MD
NCT ID: NCT04317534
Sites in Iowa:
  • University of Iowa Hospitals and Clinics — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Iowa:
  • University of Iowa — Iowa City, Iowa
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Mercy Hospital — Cedar Rapids, Iowa
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Iowa:
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
  • Physicians' Clinic of Iowa PC — Cedar Rapids, Iowa
  • Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
  • Mercy Cancer Center-West Lakes — Clive, Iowa
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Iowa:
  • Massive Bio SYNERGY-AI site — Iowa City, Iowa
Recruiting Academic/Other

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…

Sponsor: Addario Lung Cancer Medical Institute
NCT ID: NCT06486428
Sites in Iowa:
  • Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, Iowa
NA Recruiting Academic/Other

Autoimmune Intervention Mastery Course Study

The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, post acute sequela of…

Sponsor: Terry L. Wahls
NCT ID: NCT05057676
Sites in Iowa:
  • Univeristy of Iowa — Iowa City, Iowa

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25